Publicaciones en colaboración con investigadores/as de Hospital do Meixoeiro (50)

2019

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: Twoyear follow-up of the SYNTAX II study

    EuroIntervention, Vol. 15, Núm. 3, pp. E244-A252

  2. Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial

    Catheterization and Cardiovascular Interventions, Vol. 94, Núm. 7, pp. 917-925

  3. Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial

    The Lancet, Vol. 393, Núm. 10175, pp. 987-997

2018

  1. Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: Insights from five-year follow-up of the EXAMINATION trial

    EuroIntervention, Vol. 13, Núm. 16, pp. 1939-1945

  2. Cost-effectiveness of everolimus-eluting versus bare-metal stents in ST-segment elevation myocardial infarction: An analysis from the EXAMINATION randomized controlled trial

    PLoS ONE, Vol. 13, Núm. 8

  3. Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: Final five-year results of the CENTURY II randomised clinical trial

    EuroIntervention, Vol. 14, Núm. 3, pp. e343-e351

  4. Role of ST-Segment Resolution in Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention (from the 5-Year Outcomes of the EXAMINATION [Evaluation of the Xience-V Stent in Acute Myocardial Infarction] Trial)

    American Journal of Cardiology, Vol. 121, Núm. 9, pp. 1039-1045

2017

  1. Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study

    European Heart Journal, Vol. 38, Núm. 42, pp. 3124-3134

  2. Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST–Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation

    American Journal of Cardiology, Vol. 120, Núm. 9, pp. 1460-1466

  3. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: Insights from the five-year follow-up of the EXAMINATION trial

    EuroIntervention, Vol. 13, Núm. 5, pp. e557-e563

  4. Outcomes and predictors of success and complications for paravalvular leak closure: An analysis of the Spanish realwOrld paravalvular LEaks closure (HOLE) registry

    EuroIntervention, Vol. 12, Núm. 16, pp. 1962-1968

  5. Randomized comparison of ridaforolimusand zotarolimus-eluting coronary stents in patients with coronary artery disease: Primary results from the BIONICS trial (BioNIR ridaforolimus-eluting coronary stent system in coronary stenosis)

    Circulation, Vol. 136, Núm. 14, pp. 1304-1314

2016

  1. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial

    The Lancet, Vol. 387, Núm. 10016, pp. 357-366

  2. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): A multicentre, randomised, double-blind, placebo-controlled trial

    The Lancet, Vol. 387, Núm. 10014, pp. 136-145

  3. Significance of prior percutaneous revascularisation in patients with acute coronary syndromes: Insights from the prospective PROSPECT registry

    EuroIntervention, Vol. 11, Núm. 13, pp. 1468-1474

2015

  1. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial

    The Lancet, Vol. 385, Núm. 9962, pp. 43-54

  2. Acceso radial frente a femoral en angioplastia por infarto agudo de miocardio con elevación del segmento ST con stent farmacoactivo de segunda generación

    Revista Espanola de Cardiologia, Vol. 68, Núm. 1, pp. 47-53

  3. Everolimus-eluting stent versus bare-metal stent in elderly (≥ 75 years) versus non-elderly (< 75 years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial

    International Journal of Cardiology, Vol. 179, pp. 73-78

  4. Polymer-free drug-coated coronary stents in patients at high bleeding risk

    New England Journal of Medicine, Vol. 373, Núm. 21, pp. 2038-2047

  5. Predictors of adverse events among patients undergoing primary percutaneous coronary intervention: Insights from a pooled analysis of the COMFORTABLE AMI and EXAMINATION trials

    EuroIntervention, Vol. 11, Núm. 4, pp. 391-398